The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Castro, Daniela [1 ]
Tripathi, Nishita [2 ]
Sayegh, Nicolas [2 ]
Gebrael, Georges [2 ]
Li, Xiaochen [1 ]
Meza, Luis [1 ]
Zengin, Zeynep [1 ]
Chehrazi-Raffle, Alex [1 ]
Govindarajan, Ameish [1 ]
Dizman, Nazli [1 ,3 ]
Ebrahimi, Hedyeh [1 ]
Chawla, Neal [1 ]
Mercier, Benjamin [1 ]
Hsu, Joann [1 ]
Shi, Jessica [1 ]
Philip, Errol [4 ]
Bergerot, Cristiane [5 ]
Barragan-Carrillo, Regina [1 ,6 ]
Pal, Sumanta [1 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA
[2] Univ Utah, Huntsman Canc Inst, Div Med Oncol, Salt Lake City, UT USA
[3] Yale Univ, Dept Internal Med, Sch Med, New Haven, CT USA
[4] Univ Calif San Francisco, San Francisco, CA USA
[5] Ctr Canc Brasilia CETTRO, Inst Unity Ensino & Pesquisa, Brasilia, DF, Brazil
[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico
来源：
ONCOLOGIST | 2023年 / 28卷
关键词：
insurance status; clinical outcomes; disparities; social determinants of health;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
45
引用
收藏
页码：S5 / +
页数：2
相关论文
共 50 条
  • [41] The impact of staging by positron emission tomography (PET) on overall survival (OS) and progression-free survival (PFS) in the phase III PROCLAIM study
    Iscoe, N.
    Govindan, R.
    Hossain, A. M.
    San Antonio, B.
    Chouaki, N.
    Koczywas, M.
    Vokes, E.
    Senan, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [42] DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
    Peters, Inga
    Dubrowinskaja, Natalia
    Abbas, Mahmoud
    Seidel, Christoph
    Kogosov, Michael
    Scherer, Ralph
    Gebauer, Kai
    Merseburger, Axel S.
    Kuczyk, Markus A.
    Gruenwald, Viktor
    Serth, Juergen
    PLOS ONE, 2014, 9 (03):
  • [43] Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α)
    Cella, D.
    Li, J. Z.
    Cappelleri, J. C.
    Bushmakin, A.
    Charbonneau, C.
    Kim, S. T.
    Chen, I.
    Michaelson, M. D.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] PROGRESSION-FREE SURVIVAL (PFS) IS CORRELATED WITH OVERALL SURVIVAL (OS) IN CLINICAL STUDIES OF TARGETED THERAPIES PLUS CHEMOTHERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC)
    Sidhu, Roger
    Rong, Alan
    Dahlberg, Steve
    ANNALS OF ONCOLOGY, 2011, 22 : v120 - v120
  • [45] Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.
    Sjoquist, Katrin Marie
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Adams, Richard
    Seymour, Matthew T.
    Saltz, Leonard
    Schmoll, Hans
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [46] Evaluation of overall survival (OS), progression-free survival (PFS), or time to progression (TTP) in systematic review of randomized clinical trials (RCT) in patients with metastatic breast cancer (MBC)
    Mukonje, Terence
    Santana-Davila, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.
    Woodford, Rachel
    Zhou, Deborah
    Kok, Peey-Sei
    Lord, Sally
    Friedlander, Michael
    Marschner, Ian
    Simes, John
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
    Venook, Alan P.
    Niedzwiecki, Donna
    Innocenti, Federico
    Fruth, Briant
    Greene, Claire
    O'Neil, Bert H.
    Shaw, James Edward
    Atkins, James Norman
    Horvath, Laura E.
    Polite, Blase N.
    Meyerhardt, Jeffrey A.
    O'Reilly, Eileen Mary
    Goldberg, Richard M.
    Hochster, Howard S.
    Blanke, Charles David
    Schilsky, Richard L.
    Mayer, Robert J.
    Bertagnolli, Monica M.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] Progression-free survival 'doubles' in renal cell carcinoma
    Fricker, Janet
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (10) : 555 - 555
  • [50] Circulating mir-21 and mir-378 are predictive of progression-free survival (PFS) in patients treated with everolimus in metastatic renal cell cancer (mRCC).
    Chen, James Lin
    Rathmell, Kimryn
    McDermott, David F.
    Stadler, Walter Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345